ArticleInternational journal of clinical and experimental pathology2018
Cluster of specified microRNAs in tissues and serum as biomarkers for early diagnosis of hepatocellular carcinoma.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Diagnostic Value of Circulating microRNAs for Hepatocellular Carcinoma: Results of a Meta-analysis and Validation.Biochemical genetics · 2026Pooled it
- The Diagnostic Value of MicroRNAs as a Biomarker for Hepatocellular Carcinoma: A Meta-Analysis.BioMed research international · 2019Pooled it
- Circulating microRNAs as promising diagnostic biomarkers for hepatocellular carcinoma: a systematic review and meta-analysis.Frontiers in molecular biosciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHepatocellular carcinoma (HCC) is a global public health concern that lacks efficient methods for early diagnosis. Accumulated evidence has revealed great potential using microRNAs (miRNAs) as noninvasive biomarkers in HCC detection.
methodsSerum miRNAs (miR21, miR122, miR-214, miR15b, and let-7f) were detected in 75 patients with HCC and 80 healthy controls (HC). In addition, 75 HCC tissues and paired normal adjacent tissues were also analyzed for comparison. Quantified by real-time quantitative RT-PCR was used to evaluate the expression of miRNAs.
resultsWe discovered significant up-regulation of miR-21 (P < 0.001) and miR-15b (P < 0.001) as well as a down-regulation of miR-122 (P = 0.01) in HCC tissues compared to adjacent non-tumor tissues. Additionally, miR-21 (P < 0.001) and miR-15b (P < 0.001) levels were upregulated in serum and miR-214 (P = 0.01) was decreased in HCC patients compared to that in healthy controls. Multivariate logistic regression analysis showed that serum miR-21 (OR = 1.68, P = 0.012) and miR-15b (OR = 1.736,
conclusionOur results suggest that these serum miRNAs may be useful markers for discriminating HCC patients from healthy controls. Combined determination of circulating miR-21, miR-122, miR-214, and miR-15b has great potential to serve as an accurate and noninvasive biomarker for the early HCC preliminary screening.
Indexed as
Identifiers
31938193PMC6958011What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.